Glenmark’s US arm recalling affected lot of Diltiazem Hydrochloride extended-release capsules

16 Dec 2024 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc is recalling the affected lot of Diltiazem Hydrochloride extended-release capsules in the US market due to cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit. Diltiazem Hydrochloride extended-release capsules are used to treat high blood pressure. The company initiated the Class II nationwide (US) recall on November 1, 2024.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 


Glenmark Pharma Share Price

1528.55 15.95 (1.05%)
18-Dec-2024 14:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1801.90
Dr. Reddys Lab 1275.90
Cipla 1476.40
Lupin 2100.35
Zydus Lifesciences 981.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.